Importer of Controlled Substances; Notice of Registration; Clinical Supplies Management, Inc., 38084-38085 [2012-15620]

Download as PDF 38084 Federal Register / Vol. 77, No. 123 / Tuesday, June 26, 2012 / Notices By order of the Commission. Issued: June 20, 2012. Lisa R. Barton, Acting Secretary to the Commission. [FR Doc. 2012–15490 Filed 6–25–12; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE rmajette on DSK2TPTVN1PROD with NOTICES Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act (‘‘CERCLA’’) Notice is hereby given that on June 18, 2012 a proposed consent decree (‘‘proposed Decree’’) in United States v. Enstar LLC, Civil Action No. 1:12–cv– 01563–MSK was lodged with the United States District Court for the District of Colorado. In this action under Section 107(a) of the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. 9607(a) (‘‘CERCLA’’), the United States sought reimbursement of response costs incurred or to be incurred for response actions taken at or in connection with the release or threatened release of hazardous substances at the Butterfly and Burrell Mine Site, (the ‘‘Site’’) located in the White River National Forest in Rio Blanco County, approximately fourteen miles from the Town of Meeker, Colorado. The proposed Decree requires the settling defendant to pay $2,486,440 to the United States and the State in reimbursement of past response and future response costs. The proposed Decree provides the settling defendants with a covenant not to sue under Sections 106 and 107(a) of CERCLA, 42 U.S.C. 9606 and 9607(a). The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the proposed Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and either emailed to pubcomment-ees.enrd@usdoj.gov or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to United States v. the Enstar LLC, D.J. Ref. DJ # 90–11–3–10348. During the public comment period, the proposed Decree may be examined on the following Department of Justice Web site: https://www.usdoj.gov/enrd/ Consent_Decrees.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, or VerDate Mar<15>2010 15:33 Jun 25, 2012 Jkt 226001 by faxing or emailing a request to ‘‘Consent Decree Copy’’ EESCDCopy. ENRD@USDOJ.gov, fax number 202– 514–0097, phone confirmation number: 202–514–5271. If requesting a copy from the Consent Decree Library by mail, please enclose a check in the amount of $8.50 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by email or fax, forward a check in that amount to the Consent Decree Library at the stated address. Robert Brook, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2012–15438 Filed 6–25–12; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Notice of Lodging of a Consent Decree Under the Clean Water Act Notice is hereby given that on June 20, 2012, a proposed Consent Decree (‘‘CD’’) in United States et al. v. Toll Brothers, Inc., et al., Civil Action No. 12–3489, was lodged with the United States District Court for the Eastern District of Pennsylvania. In this action the United States brought claims against Toll Brothers, Inc. and seven of its wholly-owned subsidiaries (‘‘Toll’’) for violations of National Pollutant Discharge Elimination System (‘‘NPDES’’) permits which are federally-enforceable under Section 309 of the Clean Water Act (‘‘CWA’’), 33 U.S.C. 1319. The State of Maryland and the Commonwealth of Virginia joined this case as co-plaintiffs (‘‘State Plaintiffs’’). The CD addresses Toll’s violations of the CWA as well as violations of state and Federal NPDES permits governing the discharge of storm water from Toll’s home construction sites. The CD resolves the claims of the United States and State Plaintiffs for past violations at 370 construction sites by requiring the payment of a civil penalty of $741,000 and the institution of injunctive relief in the form of a nation-wide management, reporting, and training program to improve Toll’s compliance with storm water requirements at Toll’s current and future construction sites. The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the CD. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and either emailed to pubcomment-ees.enrd@usdoj.gov or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 20044–7611, and should refer to United States et al. v. Toll Brothers, Inc., et al., D.J. Ref. No. 90–5–1–1–09301. During the public comment period, the CD may also be examined on the following Department of Justice Web site, to https://www.usdoj.gov/enrd/ Consent_Decrees.html. A copy of the CD may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or emailing a request to ‘‘Consent Decree Copy’’ (EESCDCopy.ENRD@usdoj.gov), fax no. (202) 514–0097, phone confirmation number (202) 514–5271. If requesting a copy from the Consent Decree Library by mail, please enclose a check in the amount of $ 37.75 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if requesting by email or fax, forward a check in that amount to the Consent Decree Library at the address given above. In requesting a copy exclusive of exhibits, please enclose a check in the amount of $ 20.25 (25 cents per page reproduction cost) payable to the U.S. Treasury. Robert D. Brook, Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2012–15478 Filed 6–25–12; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration; Clinical Supplies Management, Inc. By Notice dated April 17, 2012, and published in the Federal Register on April 26, 2012, 77 FR 24984, Clinical Supplies Management, Inc., 342 42nd Street South, Fargo, North Dakota 58103, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Sufentanil (9740), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance with the sole purpose of packaging, labeling, and distributing to customers which are qualified clinical sites conducting clinical trials under the auspices of an FDA-approved clinical study. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Clinical Supplies Management, Inc., to import the basic class of controlled substance is consistent with the public E:\FR\FM\26JNN1.SGM 26JNN1 38085 Federal Register / Vol. 77, No. 123 / Tuesday, June 26, 2012 / Notices interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Clinical Supplies Management, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: June 18, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–15620 Filed 6–25–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application; Cambrex Charles City, Inc. Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on May 4, 2011, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616–3466, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances: Drug Schedule rmajette on DSK2TPTVN1PROD with NOTICES 4–Anilino-N-phenethyl-4-piperidine (8333). Phenylacetone (8501) .................. Opium, raw (9600) ....................... Poppy Straw Concentrate (9670) II II II II The company plans to import the listed controlled substances for internal use, and to manufacture bulk intermediates for sale to its customers. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007). Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act [21 U.S.C. 952 (a)(2)(B)] may, in the circumstances set VerDate Mar<15>2010 15:33 Jun 25, 2012 Jkt 226001 forth in 21 USC 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 26, 2012. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: June 18, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–15622 Filed 6–25–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration; Stepan Company By Notice dated May 11, 2012, and published in the Federal Register on May 21, 2012, 77 FR 30025, Stepan Company, Natural Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Coca Leaves (9040) a basic class of controlled substance in schedule II. The company plans to import the listed controlled substance to manufacture bulk controlled substance for distribution to its customer. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007). PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Stepan Company to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Stepan Company to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: June 18, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–15621 Filed 6–25–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Cayman Chemical Company By Notice dated March 8, 2012, and published in the Federal Register on March 20, 2012, 77 FR 16263, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug 4-Methyl-N-methylcathinone (1248). Gamma Hydroxybutyric Acid (2010). Mescaline (7381) .......................... N-Benzylpiperazine (7493) ........... 3,4-Methylenedioxyprovalerone (7535). 3,4-Methylenedioxy-Nmethylcathinone (7540). Schedule I I I I I I The company plans to manufacture the above listed controlled substances to supply these materials to the research and forensics community for drug testing and analysis. E:\FR\FM\26JNN1.SGM 26JNN1

Agencies

[Federal Register Volume 77, Number 123 (Tuesday, June 26, 2012)]
[Notices]
[Pages 38084-38085]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15620]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration; 
Clinical Supplies Management, Inc.

    By Notice dated April 17, 2012, and published in the Federal 
Register on April 26, 2012, 77 FR 24984, Clinical Supplies Management, 
Inc., 342 42nd Street South, Fargo, North Dakota 58103, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of Sufentanil (9740), a basic class of 
controlled substance listed in schedule II.
    The company plans to import the listed controlled substance with 
the sole purpose of packaging, labeling, and distributing to customers 
which are qualified clinical sites conducting clinical trials under the 
auspices of an FDA-approved clinical study.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the 
registration of Clinical Supplies Management, Inc., to import the basic 
class of controlled substance is consistent with the public

[[Page 38085]]

interest and with United States obligations under international 
treaties, conventions, or protocols in effect on May 1, 1971. DEA has 
investigated Clinical Supplies Management, Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic class of controlled substance 
listed.

     Dated: June 18, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-15620 Filed 6-25-12; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.